FDA Panel Endorses Gene Therapy For A Form Of Childhood Blindness

A panel of experts has recommended that the Food and Drug Administration approve a treatment developed by Spark Therapeutics for a rare form of blindness.

Food and Drug Administration advisers unanimously recommended that the agency approve the first gene therapy for an inherited disease — a rare defect that causes blindness in children.

(Image credit: Spark Therapeutics)